Epidemiology

Sessions

Wednesday, 23 November

10:50

Gambling Research

10:50 to 12:20

Insights zone 3 (I3)

Oral presentation session

13:20

Gambling epidemiology and new trends

13:20 to 14:50

Insights zone 3 (I3)

Oral presentation session

15:00

Estimating harm

15:00 to 16:30

Central square 3 (C3)

Oral presentation session

Estimating prevalence

15:00 to 16:30

Knowledge market 4 (K4)

Oral presentation session

Injecting-related infections and drug surveillance

15:00 to 16:30

Knowledge market 3 (K3)

Oral presentation session

Spillover effects of drug policy and why better data are needed

15:00 to 16:30

Networking zone 1 (N1)

e-poster guided tour

Substance use and mental health disorders in Europe: prevalence, models of care, and implementation in a challenging COVID-19 context

15:00 to 16:30

Knowledge market 2 (K2)

Structured session

Surveillance

15:00 to 16:30

Networking zone 4 (N4)

Short communication session

16:50

Alcohol use disorder treatment and its epidemiology

16:50 to 18:20

Central square 1 (C1)

Oral presentation session

Driving under the influence of cannabis (DUIC)

16:50 to 18:20

Insights zone 3 (I3)

Structured session

Focusing on gender issues

16:50 to 18:20

Central square 3 (C3)

Oral presentation session

Thursday, 24 November

09:00

The Spanish Network on Research on Primary Attention on Addiction (RIAPAd): a new multilevel integrated model of responsible research on Addiction Disorders

09:00 to 10:30

Knowledge market 4 (K4)

Structured session

10:50

Cannabis use and purchase behaviours in Canada, United States, Australia, and New Zealand: Findings from the International Cannabis Policy Study

10:50 to 12:20

Knowledge market 1 (K1)

Structured session

Current international evidence on prevalence and perceptions of Heated Tobacco Products (HTPs)

10:50 to 12:20

Insights zone 4 (I4)

Structured session

Problematic internet and videogame use

10:50 to 12:20

Insights zone 3 (I3)

Oral presentation session

13:20

Methods and Problems with Estimating Prevalence of People Who Inject Drugs, studies and debate on how to get better and more consistent estimates in Europe and Rest of the World

13:20 to 14:50

Central square 2 (C2)

Structured session

15:00

Alcohol epidemiology and interventions

15:00 to 16:30

Networking zone 3 (N3)

Short communication session

Insights into acute recreational drug and new psychoactive substance toxicity – an update from the Euro-DEN Plus Project

15:00 to 16:30

Central square 2 (C2)

Structured session

The future of surveys in the field of alcohol research: Lessons learned from a large-scale European survey (DEEP SEAS project)

15:00 to 16:30

Central square 1 (C1)

Structured session

16:50

Insights from treatment I

16:50 to 18:20

Central square 3 (C3)

Oral presentation session

Prison and drugs: exploring social determinants and pathways to drug problem and incarceration

16:50 to 18:20

Central square 1 (C1)

Structured session

Reducing harm - obstacles and opportunities

16:50 to 18:20

Networking zone 1 (N1)

e-poster guided tour

Substance use, suicide and self-harm: epidemiology and prevention

16:50 to 18:20

Main stage

Structured session

Young people, substance use and prevention

16:50 to 18:20

Knowledge market 3 (K3)

Oral presentation session

Friday, 25 November

09:00

Alcohol addiction; new knowledge on politics, risks, treatments and outcomes

Social inequality in drinking, underage drinking and alcohol industry

09:00 to 10:30

Main stage

Plenary session

10:50

A Digital Future? Engaging online communities of people who use drugs to influence policy and practice

10:50 to 12:20

Central square 4 (C4)

Workshop

COVID-19-adapted addiction services and impact for service users

10:50 to 12:20

Insights zone 4 (I4)

Structured session

Mortality among people who use drugs

10:50 to 12:20

Knowledge market 3 (K3)

Oral presentation session

Substance use and prison

10:50 to 12:20

Central square 1 (C1)

Oral presentation session

13:20

Alcohol psychology and some epidemiology

13:20 to 14:50

Networking zone 4 (N4)

Short communication session

Changes and trends in how people are buying drugs

13:20 to 14:50

Insights zone 4 (I4)

Oral presentation session

New advances in alcohol clinical research: evidence from three large National Institute for Health Research-funded randomised controlled trials

13:20 to 14:50

Networking zone 3 (N3)

Structured session

Substance use, mental health risk and suicide

13:20 to 14:50

Knowledge market 2 (K2)

Oral presentation session

Understanding drug use, risk and harm

13:20 to 14:50

Networking zone 2 (N2)

e-poster guided tour

Using innovative data or methods to assess drug markets and drug policy impacts

13:20 to 14:50

Knowledge market 1 (K1)

Oral presentation session

15:00

The Richard Hartnoll memorial lecture

15:00 to 15:30

Main stage

Plenary session

Presentations

Wednesday, 23 November

10:50

Oral presentation

Treatment-seeking problem gamblers: characteristics of individuals who offend to finance gambling

Characterizing habit formation in modern slot machine gambling

A scoping review on cryptocurrency trading among young people and its association with gambling and mental health

Cue-reactivity and inhibitory control in behavioral addcitions: an overview of functional neuroimaging studies

13:20

Cryptocurrency trading as behavioral addiction: cross-sectional and longitudinal perspective from Finland

Online gambling and associated harms during the COVID-19 pandemic: A population study

Online gambling and F2P games in Canada: portrait and trends

Problem gambling among European adolescents: potential risk of gambling products and online gambling

15:00

Detection of Potent 'Nitazene' Synthetic Opioids by a networked drug checking service in Toronto, Ontario, Canada

15:00 to 16:30

Networking zone 4 (N4)

Kristy Scarfone

Short communication

Access to medical cannabis in Brazil: informal regulation via patient associations as a social movement

15:00 to 16:30

Networking zone 4 (N4)

Paulo J. R. Pereira

Short communication

Method development for monitoring Google-indexed e-shops offering new psychoactive substances (NPS) in The Netherlands.

15:00 to 16:30

Networking zone 4 (N4)

Lavinia Stegemann

Short communication

How to evaluate complex drug policies? A case study of the Belgian drug policy

15:00 to 16:30

Networking zone 4 (N4)

Eva Blomme

Short communication

The Unit of Cannabis: from a systematic review to a NIDA recommendation

15:00 to 16:30

Networking zone 4 (N4)

María Teresa Pons-cabrera

Short communication

A longitudinal study of a drug checking service for patrons of Boom Festival 2018: behavioral outcomes at individual and group levels.

15:00 to 16:30

Networking zone 4 (N4)

Helena Valente

Short communication

Using Reddit Social Media Data to Uncover Self-medication and Drug Use Trends among Opioid Users: Semi-automated Natural Language Processing Approach.

15:00 to 16:30

Networking zone 4 (N4)

Georgiy Bobashev

Short communication

Findings from novel methods of surveillance for fentanyl and novel psychoactive substances within Supervised Injecting Facilities

15:00 to 16:30

Networking zone 4 (N4)

Suzanne Nielsen

Oral presentation

1. What do we mean by psychiatric comorbidity or dual disorders?

15:00 to 16:30

Knowledge market 2 (K2)

Marta Torrens

Oral presentation

2. Impact of Covid19 on mental health and drug use: main findings from the EMCDDA trendspotter study

15:00 to 16:30

Knowledge market 2 (K2)

Franca Beccaria

Oral presentation

3. Psychiatric comorbidity in the European countries: prevalence and models of care

15:00 to 16:30

Knowledge market 2 (K2)

Francina Fonseca

Oral presentation

4. The dual diagnosis inpatient and outpatient treatment program in Ljubljana: practical implementatio

15:00 to 16:30

Knowledge market 2 (K2)

Nusa Segrec, Andrej Kastelic

Discussion

Discussion: Substance use and mental health disorders in Europe

15:00 to 16:30

Knowledge market 2 (K2)

Gabriele Fischer

Oral presentation

Fear of inpatient opioid withdrawal: Addressing a modifiable barrier to health-care access for people who use illicit opioids.

15:00 to 16:30

Knowledge market 3 (K3)

Magdalena Harris

Oral presentation

Analysis of drugs in used syringes from sentinel European cities, 2020

15:00 to 16:30

Knowledge market 3 (K3)

Thomas Seyler

Oral presentation

The impact of opioid agonist treatment on hospitalisations for injecting-related diseases: a retrospective data linkage study

15:00 to 16:30

Knowledge market 3 (K3)

Samantha Colledge-Frisby

e-poster

Association of the 2016 UK Psychoactive Substance Act with hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure.

15:00 to 16:30

Networking zone 1 (N1)

Sam Craft

e-poster

Is there a long-term relationship between cannabis and heroin use? An 18-20-year follow-up of the Australian Treatment Outcome Study (ATOS)

15:00 to 16:30

Networking zone 1 (N1)

Jack Wilson

e-poster

Do Medical Cannabidiol Laws Reduce Nonfatal and Fatal Opioid Overdose Rates?

15:00 to 16:30

Networking zone 1 (N1)

Rahi Abouk

e-poster

Regulating cannabis : a comparative perspective on policy rollouts and unintended consequences in The United States and Canada (lessons from 6 case studies)

15:00 to 16:30

Networking zone 1 (N1)

Ivana Obradovic

e-poster

The Effects of Recreational Cannabis Laws on Pharmacy- and Hospital-Based Opioid Distribution in the United States

15:00 to 16:30

Networking zone 1 (N1)

Coleman Drake

Oral presentation

Utilising data linkage to describe and explore mortality among a retrospective cohort of individuals admitted to residential substance use treatment.

15:00 to 16:30

Central square 3 (C3)

Tisdale Calvert

Oral presentation

It is logically not possible to quantify the number of indirect deaths

15:00 to 16:30

Central square 3 (C3)

Alfred Uhl

Oral presentation

Mortality and Morbidity in Patients in Opioid Maintenance Treatment

15:00 to 16:30

Central square 3 (C3)

Roman Gabrhelík

Oral presentation

Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment and race and ethnicity for the United States 2000-2018.

15:00 to 16:30

Central square 3 (C3)

Charlotte Buckley

Oral presentation

Mortality consequences of misuse of psychoactive prescription drugs in Portugal - the MisuMedPT project

15:00 to 16:30

Central square 3 (C3)

Ana Araújo

Oral presentation

How does risk prevention (not) work? Learning from the realist, pragmatic, cluster-randomised trial of the RISKIT-CJS programme (with a null result)

15:00 to 16:30

Knowledge market 4 (K4)

Nadine Hendrie

Oral presentation

Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise

15:00 to 16:30

Knowledge market 4 (K4)

Vivian Hope

Oral presentation

Prevalence and socio-demographics correlates of cannabis vaping: Results from the 2018 & 2019 International Cannabis Policy Study

15:00 to 16:30

Knowledge market 4 (K4)

Gary Chan

Oral presentation

Systematic review and meta-analysis of the prevalence of prescription opioid dependence in patients with chronic non cancer pain (CNCP) treated with opioid painkillers

15:00 to 16:30

Knowledge market 4 (K4)

Kyla Thomas

Oral presentation

Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: the ETHOS Engage Study

15:00 to 16:30

Knowledge market 4 (K4)

Jason Grebely

Oral presentation

Association of opioid agonist treatment with mortality or rehospitalization following injection drug use-associated bacterial and fungal infections: linkage cohort study

15:00 to 16:30

Knowledge market 3 (K3)

Thomas Brothers

16:50

Oral presentation

Community involvement facilitating the discussion of alcohol use in primary care: A nominal group study

16:50 to 18:20

Central square 1 (C1)

Bram Pussig

Oral presentation

Modeling the Impact of a long-term horizon and multiple treatment episodes on the effectiveness and cost-effectiveness of alcohol treatment in the United States

16:50 to 18:20

Central square 1 (C1)

Carolina Barbosa

Oral presentation

Per capita alcohol consumption and alcohol-related harm: an analysis of long-term evidence from Nordic and Mediterranean countries

16:50 to 18:20

Central square 1 (C1)

Gregor Zwirn

Oral presentation

The modelled cost-effectiveness of two psychological treatments for the reduction of alcohol consumption in alcohol-dependent individuals

16:50 to 18:20

Central square 1 (C1)

Sergio Flores

Oral presentation

Can alcohol abstinence orders reduce mortality? Insights from an individual-level analysis of 24/7 Sobriety

16:50 to 18:20

Central square 1 (C1)

Beau Kilmer

Oral presentation

An international rapid review of the needs and an indirect estimate of the national prevalence of women who use substances and endure domestic violence.

16:50 to 18:20

Central square 3 (C3)

Catherine Comiskey

Oral presentation

1. Experimental studies on cannabis and driving impairment

What are the attitudes of pregnant women and mothers concerning maternal alcohol use, and what factors are associated with increased maternal drinking?

16:50 to 18:20

Central square 3 (C3)

Abi Rose

Oral presentation

2. Epidemiological studies on cannabis and crash risk

Identifying the needs of mothers in substance use treatment services using electronic health records

16:50 to 18:20

Central square 3 (C3)

Martha Canfield

Oral presentation

3. Toxicology: detection of THC impairment

Metzineres. Environments of Shelter for Womxn who use drugs surviving violence

16:50 to 18:20

Central square 3 (C3)

Aura Roig Forteza

Oral presentation

4. Policy and legislation

Prevalence of Tobacco Smoking in Austria. Differences between Women and Men

16:50 to 18:20

Central square 3 (C3)

Irene Schmutterer

Oral presentation

5. Medical use and novel cannabinoids

16:50 to 18:20

Insights zone 3 (I3)

Robyn Robertson

Thursday, 24 November

09:00

Oral presentation

3. Promotion of health regarding the problematic drug use through interventions in educational and primary addiction treatment settings

09:00 to 10:30

Knowledge market 4 (K4)

Victor Villanueva

Oral presentation

4. Translational research as a necessary actor for fighting addiction: RIAPAd as a coordinated national cooperative framework

09:00 to 10:30

Knowledge market 4 (K4)

Fernando Rodriguez De Fonseca

Discussion

What is next on Addiction Research? A responsible innovative approach to societal changes in Addiction

09:00 to 10:30

Knowledge market 4 (K4)

Marta Torrens, Fernando Rodriguez De Fonseca

Oral presentation

1. Implementing patient-reported experiences (PROMs and PREMs) to improve the engagement of patients in treatment services

09:00 to 10:30

Knowledge market 4 (K4)

Joan-Ignasi Mestre-Pintó

Oral presentation

2. New challenges in drug monitoring: wastewater analysis as an alternative indicators for rapid epidemiological assessment of drug use trend

09:00 to 10:30

Knowledge market 4 (K4)

José Benito Quintana

10:50

Oral presentation

5. It’s not what you’d term normal smoking’: A qualitative exploration of HTP user identity

1. Global Prevalence of Heated Tobacco Product Use: A Systematic Review and Meta-analysis

2. HTP prevalence in England and use for smoking cessation

3. Perceived health risks of heated tobacco products, tobacco cigarettes, and e-cigarettes: Findings from a populationbased cross-sectional household survey in Germany (DEBRA study)

10:50 to 12:20

Insights zone 4 (I4)

Stephanie Klosterhalfen

Oral presentation

4. Harm perceptions of heated tobacco products and vaping among students at Lithuanian universities

Assessment of Criteria for Specific Internet-use Disorders (ACSID-11):Further development and validation of a new screening instrument capturing ICD-11 criteria for gaming disorder and other potential Internet-use disorders

Problematic gaming risk among European adolescents: A cross-national evaluation of individual and socio-economic factors

Effects of COVID-19 lockdowns on addiction to social networking sites and associations with changes in loneliness, sexual functioning, and eating styles

Experienced gratification and compensation in addictive behaviors: Investigating its relevance in different types of Internet-use disorders

Understanding first controlled gaming in teenagers. A qualitative study among young French daily or week-end gamers

1. The International Cannabis Policy Study – Framework for evaluating cannabis legalization

10:50 to 12:20

Knowledge market 1 (K1)

David Hammond

Oral presentation

2. Patterns of problematic cannabis use among Canadian and US respondents between 2018 and 2020: Findings from the International Cannabis Policy Study

10:50 to 12:20

Knowledge market 1 (K1)

Cesar Leos-Toro

Oral presentation

3. Perceptions of illegal and legal cannabis in Canada in the three years after cannabis legalization: Findings from the International Cannabis Policy Study

10:50 to 12:20

Knowledge market 1 (K1)

TBD TBD

13:20

Oral presentation

2. Estimating the prevalence of opioid dependence in New South Wales from multiple data sources: case study application of a Bayesian modelling approach

13:20 to 14:50

Central square 2 (C2)

Hayley E. Jones

Oral presentation

3. Estimates of people who injected drugs within the past 12 months in France

13:20 to 14:50

Central square 2 (C2)

Eric Janssen

Oral presentation

4. How many people injected illicit drugs in the European Union in 2019?

13:20 to 14:50

Central square 2 (C2)

Filippo Pericoli

Oral presentation

1. Estimates of people who injected drugs within the last 12 months in Belgium

13:20 to 14:50

Central square 2 (C2)

Luk Van Baelen

Oral presentation

5. Updated global estimates of prevalence of People Who Inject Drugs and coverage of harm reduction – what has changed between 2017 and 2021

13:20 to 14:50

Central square 2 (C2)

Samantha Colledge-Frisby

15:00

Short communication

Alcohol and other drug use and treatment for Aboriginal Australians involved in the criminal justice system

15:00 to 16:30

Networking zone 3 (N3)

Michael Doyle

Short communication

Effectiveness of regulatory policies on online/digital/internet – mediated alcohol marketing: a systematic review

15:00 to 16:30

Networking zone 3 (N3)

Sandra Rados Krnel

Short communication

Outcomes of a health economic evaluation of digital alcohol and tobacco interventions for cancer survivors alongside randomized controlled trials

15:00 to 16:30

Networking zone 3 (N3)

Matthijs Blankers

Short communication

Impact of digital alcohol marketing on alcohol-related attitudes and alcohol consumption

15:00 to 16:30

Networking zone 3 (N3)

Wim Van Dalen

Short communication

Benefits and Challenges of Integrating Yoga in Government-Funded Substance Addiction Treatment Programs in India: Results from a Mixed Methods Research Study with Exploratory Sequential Design.

15:00 to 16:30

Networking zone 3 (N3)

Sebastian Perumbilly, Jake Zoubek, Aubrey Grodin

Oral presentation

1. Developing and Extending Evidence and Practice from the Standard European Alcohol Survey (DEEP SEAS): Key findings, strengths, and limitations

15:00 to 16:30

Central square 1 (C1)

Carolin Kilian

Short communication

The global burden of alcohol use disorders: methodological considerations

15:00 to 16:30

Networking zone 3 (N3)

Laura Jones

Oral presentation

2. Lessons for the future of alcohol surveys

15:00 to 16:30

Central square 1 (C1)

Jürgen Rehm

Discussion

The future of surveys in the field of alcohol research

15:00 to 16:30

Central square 1 (C1)

Charlotte Probst, Bernd Schulte

Short communication

Structured Leisure Activities (SLA) and Adolescent Alcohol Use

15:00 to 16:30

Networking zone 3 (N3)

Matea Belošević

Short communication

Social networks amongst people with alcohol dependence who frequently attend hospital: an exploratory qualitative study

15:00 to 16:30

Networking zone 3 (N3)

Stephanie Fincham-Campbell

Oral presentation

2. The clinical impact of ethanol co-use in patients with acute drug toxicity involving the use of central nervous system depressant recreational drugs

15:00 to 16:30

Central square 2 (C2)

Eva-Carina Heier

Oral presentation

3. Variation in the drugs involved in acute drug toxicity presentations based on age and sex within the Euro-DEN Plus dataset

15:00 to 16:30

Central square 2 (C2)

Òscar Miró

Oral presentation

4. Deaths among acute drug toxicity presentations to the Euro-DEN Plus Network, 2014-2020

15:00 to 16:30

Central square 2 (C2)

Isabelle Giraudon

Oral presentation

1. New Psychoactive Substance Presentations to the Euro-DEN Plus Network

15:00 to 16:30

Central square 2 (C2)

Benjamin Crulli

Oral presentation

3. Are there good alternatives or add ons to surveys?

15:00 to 16:30

Central square 1 (C1)

Pia Mäkelä

Oral presentation

0. Insights into acute recreational drug and NPS toxicity: an update from the Euro DEN Plus Project: Introduction

15:00 to 16:30

Central square 2 (C2)

Paul Dargan

16:50

Oral presentation

The acceptability and feasibility of implementing and evaluating the Parents under Pressure (PuP) parenting programme with opioid-dependent fathers and their families: results from the PuP4Dads study.

16:50 to 18:20

Central square 3 (C3)

Anne Whittaker

Oral presentation

Suicide and self-harm during COVID-19 and beyond.

Adolescent substance use, self-harm and suicide: Findings from the Northern Finland Birth Cohort 1986.

Restricting access to means: Public health approaches to reduce drug- and alcohol-related self-harm.

Identification of cannabis user profiles and their engagement with polydrug use among respondents of the European Web Survey on Drugs: findings from Luxembourg

16:50 to 18:20

Knowledge market 3 (K3)

Tom Kugener

Oral presentation

E-cigarette use and conventional cigarette smoking among high school students in 35 European countries: findings from the 2019 ESPAD survey

16:50 to 18:20

Knowledge market 3 (K3)

Sonia Cerrai

Oral presentation

Laughing gas (N2O) in The Netherlands: where a quick rise in use required action

16:50 to 18:20

Knowledge market 3 (K3)

Desiree Spronk

Oral presentation

Identifying subgroups of Dutch cannabis users based on help-seeking preferences: a latent class analysis

16:50 to 18:20

Knowledge market 3 (K3)

Marleen Olthof

Oral presentation

A National Recovery Study in Higher Education Institutions in Ireland

16:50 to 18:20

Knowledge market 3 (K3)

Ivers Jo-Hanna

e-poster

High smoking and low cessation rates among patients in treatment for opioid and other substance use disorders

16:50 to 18:20

Networking zone 1 (N1)

Endre D. Bjørnestad

e-poster

Hepatitis C seroprevalence and associated factors among people who inject drugs (PWID) in Estonia

16:50 to 18:20

Networking zone 1 (N1)

Sigrid Vorobjov

e-poster

An ecological analysis of the spatial relationship between a network of supervised consumption services and overdose mortality incidence in Toronto, Canada.

16:50 to 18:20

Networking zone 1 (N1)

Indhu Rammohan

Oral presentation

Ayahuasca-assisted addiction treatment in Peru: qualitative results from a multi-year, mixed-methods study

16:50 to 18:20

Central square 3 (C3)

Olivia Marcus

e-poster

Take-Home Naloxone and risk management among people who survived an opioid overdose; a qualitative analysis informed by drug, set and setting

16:50 to 18:20

Networking zone 1 (N1)

Elin Holmén

Oral presentation

EXtended-release Pharmacotherapy for Opioid Use Disorder (EXPO)

16:50 to 18:20

Central square 3 (C3)

John Marsden

e-poster

Mortality and causes of death among persons with alcohol use disorder only versus persons with opioid dependence: results from a 19-year prospective cohort study.

16:50 to 18:20

Networking zone 1 (N1)

Ivar Skeie

Oral presentation

Characteristics of concerned persons (CPs) accessing treatment services in their own right: A secondary analysis of Irish health data for 2010-2020.

16:50 to 18:20

Central square 3 (C3)

Cathy Kelleher

e-poster

Identifying and tracking cases of suspected unintentional drug overdose deaths in near real-time using the Suspected Potential Overdose Tracker (SPOT)

16:50 to 18:20

Networking zone 1 (N1)

Karli Hochstatter

e-poster

Wearable technologies that may prevent, detect or respond to opioid overdose: a scoping review.

16:50 to 18:20

Networking zone 1 (N1)

Basak Tas

e-poster

Harm reduction behaviors are associated with carrying naloxone among patients on methadone treatment.

16:50 to 18:20

Networking zone 1 (N1)

Zofia Kozak

e-poster

Knowledge and attitude of community stakeholders towards harm reduction activities including Methadone treatment, needle and syringe exchange programs for drug users and injectors in Gaza Strip-Palestine (2019)

16:50 to 18:20

Networking zone 1 (N1)

Mohammed fathi Alafifi

Discussion

Common pathways to problematic drug use and incarceration and lessons learnt for policy and practice

16:50 to 18:20

Central square 1 (C1)

Liesbeth Vandam

Oral presentation

1. Use pathways in prison. A French literature review

16:50 to 18:20

Central square 1 (C1)

Caroline Protais

Oral presentation

2. Characteristics associated with drug use during the current detention – results from prison surveys in 4 EU countriessurveys in 4 EU countries

16:50 to 18:20

Central square 1 (C1)

Els Plettinckx

Oral presentation

5. Social determinants, health service contacts and incarceration among all those dying from an accidental overdose 2010-2018 in Norway

16:50 to 18:20

Central square 1 (C1)

Ellen J. Amundsen

Oral presentation

3. Reimprisonment rates among men who inject drugs in Victoria, Australia

16:50 to 18:20

Central square 1 (C1)

Ashleigh C. Stewart

Oral presentation

4. Adverse childhood experiences, substance use, and involvement with correctional services

16:50 to 18:20

Central square 1 (C1)

Richard Pates

Oral presentation

6. Wasted': the complex trajectories from incarceration to recovery. A personal experience

16:50 to 18:20

Central square 1 (C1)

Mark Johnson Ferguson

Friday, 25 November

09:00

Keynote presentation

A social inequities viewpoint to reducing alcohol-related harm

What did we learn about recent trends in underage drinking: Secular trends, shifts, and relations to other substance use

Can brief interventions ever really take on the alcohol industry and win?

10:50

1. Revised service delivery of opioid agonist treatment in Norway in 2021, the second year of the pandemic: a national cross-sectional study of treatment provider experiences

4. Have predictors of drug addiction relapse changed during the COVID-19 pandemic? A prospective study of recovery pathways in the Netherlands, Belgium and UK

5. The impacts of COVID-19 pandemic on drug purchasing behaviours of people who use methamphetamine in Victoria, Melbourne.

2. A rapid assessment of take-home naloxone provision during COVID-19 in Europe

3. Will they accept the vaccine? A 2021 COVID-19 survey among 477 people who use drugs in Norway

10:50 to 12:20

Insights zone 4 (I4)

Gabrielle K. Welle-Strand

Oral presentation

The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018.

10:50 to 12:20

Knowledge market 3 (K3)

Nicola Jones

Oral presentation

Increased risk of non-fatal overdose associated with NPS-type [‘street’] benzodiazepine use in Scotland, UK

10:50 to 12:20

Knowledge market 3 (K3)

Andrew McAuley

Oral presentation

Variations in the protective association between opioid agonist therapy and opioid overdose death by age and chronic disease status: findings from the OATS retrospective linked data study, NSW, Australia, 2001-2018.

10:50 to 12:20

Knowledge market 3 (K3)

Sarah Larney

Oral presentation

Temporal trend in the survival of injecting and non-injecting heroin-dependent patients admitted to treatment in Barcelona, Spain: a 30-year cohort study.

10:50 to 12:20

Knowledge market 3 (K3)

Anna Hernández-Rubio

Oral presentation

Prevalence of heroin drug use before and during imprisonment in Europe: results from a comprehensive literature review and analysis of prevalence data in six European countries

10:50 to 12:20

Central square 1 (C1)

Sara Mazzilli

Oral presentation

Factors associated with mortality in The Norwegian Offender Mental Health and Addiction (NorMA)- cohort

10:50 to 12:20

Central square 1 (C1)

Torill Tverborgvik

Oral presentation

All cause and cause specific mortality among individuals imprisoned for driving under the influence of alcohol and drugs in Norway (2000-2016)

10:50 to 12:20

Central square 1 (C1)

Ragnhild Jamt

Oral presentation

The Impact of Co-Occurring Mental Health Problems on Referral to and Initiation of Treatment Among Youth Under Probation Supervision

10:50 to 12:20

Central square 1 (C1)

Steven Belenko

Oral presentation

(Ex-)inmates' substance use: a needs assessment based on semi-structured interviews

10:50 to 12:20

Central square 1 (C1)

Nicky Dirkx

Oral presentation

European Web Survey on Drugs

10:50 to 12:20

Central square 4 (C4)

João Matias, José Pedro Teixeira

Oral presentation

European Web Survey on Drugs - Luxembourg

10:50 to 12:20

Central square 4 (C4)

Rita Cardoso Seixas

Oral presentation

European Web Survey on Drugs - Ireland

10:50 to 12:20

Central square 4 (C4)

Nicki Killeen

Oral presentation

The experience of running web surveys in Belgium

10:50 to 12:20

Central square 4 (C4)

Elena Damian

Oral presentation

Web surveys on drugs - how can these be important for those who use drugs

10:50 to 12:20

Central square 4 (C4)

Lígia Parodi

13:20

Oral presentation

Monitoring online illicit drug market during the COVID-19 in Georgia

Who buys drugs using online sources in Ireland? Findings from the European Web Survey on Drugs

What can we learn from low-THC cannabis growers in Europe? A comparative transnational study of 1635 small-scale cannabis growers in Italy and Switzerland

Brokered Illegal Drug Sales as a Measure of Local Demand

Influence of alcohol use and other addictive disorders in the costs of emergency department frequent use

13:20 to 14:50

Networking zone 4 (N4)

Clara Oliveras Salvà

Short communication

Social alcohol cue reactivity in the brain: role of craving and social processes in adolescent and adult alcohol users

13:20 to 14:50

Networking zone 4 (N4)

Lauren Kuhns

Short communication

Alcohol Poisoning Outbreak in Iranian Adult Population During the COVID-19 Pandemic: A Prospective Cross-sectional Linkage Study from 13 Toxicology Referral Centers in Iran

13:20 to 14:50

Networking zone 4 (N4)

Hossein Hassanian-Moghaddam

Short communication

Novel interventions to help citizens with hazardous substance use and prevent driving under the influence of alcohol or drugs (DUI)

13:20 to 14:50

Networking zone 4 (N4)

Kristine Rømer Thomsen

Short communication

Young, drunk, and fast: the paradoxical effects of hazardous drinking on cognitive performance in younger adults

13:20 to 14:50

Networking zone 4 (N4)

Anna Powell

Short communication

A Literature Review, using a Systematic Approach, on Effective Interventions and Approaches in the Delivery of Integrated Alcohol Services in Community Settings

13:20 to 14:50

Networking zone 4 (N4)

Elizabeth McCarthy

Short communication

Initial efficacy of a new goal-oriented intervention for impulsive and sensation-seeking adolescents involving a digital game and MI-based interview

13:20 to 14:50

Networking zone 4 (N4)

Nuri Wieland

Oral presentation

Comparing characteristics of suicide to non-suicide drug poisoning, by sex, in Ireland.

13:20 to 14:50

Knowledge market 2 (K2)

Ena Lynn

Oral presentation

Characteristics associated with suicide among people who use drugs in Ireland 2015 to 2017: a repeated cross-sectional study

13:20 to 14:50

Knowledge market 2 (K2)

Suzi Lyons

Oral presentation

Implementation of a community-based psychiatric intervention among people who inject drugs in the City of Haiphong, Vietnam: the DRIVE-Mind project

13:20 to 14:50

Knowledge market 2 (K2)

Laurent Michel

Oral presentation

Hazardous, harmful and dependent alcohol use in Crisis Resolution Team patients: relationship with death or service recontact after a suicidal crisis.

13:20 to 14:50

Knowledge market 2 (K2)

John Robins

Oral presentation

The impact of detoxification on suicidal behaviour among heroin users: longitudinal data from South Africa

13:20 to 14:50

Knowledge market 2 (K2)

Nirvana Morgan

Oral presentation

TitleDeterminants of psychological distress during the COVID-19 pandemic among people who use drugs in Montreal, Canada

13:20 to 14:50

Knowledge market 2 (K2)

Iuliia Makarenko

Oral presentation

Alcohol, tobacco and cannabis use and mental health as well as other associated factors during the COVID-19 pandemic among German university students

13:20 to 14:50

Knowledge market 2 (K2)

Stefanie Helmer

Oral presentation

Cannabis regulation and fiscal policy: Opportunities for human rights in Colombia

13:20 to 14:50

Knowledge market 1 (K1)

Luis Felipe Cruz-olivera

Oral presentation

Prioritising measures to assess performance of drug treatment services: perspectives of funders, treatment providers and service users

13:20 to 14:50

Knowledge market 1 (K1)

Robert Stirling

Oral presentation

Tracking the illicit Cannabis Market during the closed Cannabis Supply Chain Experiment in Netherlands using an online Crowdsourcing Approach

13:20 to 14:50

Knowledge market 1 (K1)

Stijn Hoorens

Oral presentation

Triangulating wastewater and a prospective survey of drug consumption – new insights for policy makers

13:20 to 14:50

Knowledge market 1 (K1)

Caitlin Hughes

Oral presentation

The effects of cannabis liberalization laws on health, safety, and socioeconomic outcomes: An evidence and gap map

13:20 to 14:50

Knowledge market 1 (K1)

Eric Sevigny

e-poster

Four-year long wastewater-based monitoring of illicit drug consumption pilot project in Switzerland

13:20 to 14:50

Networking zone 2 (N2)

Livia Andrani

e-poster

How are profiles of substance use linked to social function in the following seven years?

13:20 to 14:50

Networking zone 2 (N2)

Sidsel Karsberg

e-poster

A systematic review of self-report and behavioural measures of the Addiction Neuroclinical Assessment constructs of incentive salience and negative emotionality, in adults who use psychoactive drugs.

13:20 to 14:50

Networking zone 2 (N2)

Maria Bravo Aguilera

e-poster

Abuse of prescription psychoactive medicines

13:20 to 14:50

Networking zone 2 (N2)

Darja Lavtar

e-poster

Changes in substance use during the COVID-19 pandemic: Longitudinal analysis of risk behavior and mental health of MSM using HIV pre-exposure prophylaxis

13:20 to 14:50

Networking zone 2 (N2)

Babette Lea Winter

e-poster

Non-prescribed buprenorphine and reduction in illicit opioids use among individuals with opioid use disorder: a longitudinal study

13:20 to 14:50

Networking zone 2 (N2)

Raminta Daniulaityte

e-poster

Sexualized substance use, consumption motives and risk factors for relapse of addiction patients. Results of a cross-sectional study in addiction treatment facilities in Germany.

13:20 to 14:50

Networking zone 2 (N2)

Daniel Deimel

e-poster

How hair keeps track: Associations between hair concentrations of psychoactive substances and steroid hormones in a large cohort sample of young adults in Switzerland

13:20 to 14:50

Networking zone 2 (N2)

Lydia Johnson-Ferguson

e-poster

Changes in sexualised and non-sexualised drug use among LGBT+ people during the COVID-19 pandemic: A systematic review

13:20 to 14:50

Networking zone 2 (N2)

Dean Connolly

e-poster

Suicide and self-harm among people prescribed opioid agonist treatment in New South Wales: a retrospective data linkage study

13:20 to 14:50

Networking zone 2 (N2)

Samantha Colledge-Frisby

Oral presentation

1. A novel way of enhancing adherence to acamprosate for alcohol dependence: The Alcohol Dependence and Adherence to Medicine (ADAM) trial

13:20 to 14:50

Networking zone 3 (N3)

Thomas Phillips

Oral presentation

2. Effectiveness and cost-effectiveness of face-to-face and electronic brief interventions versus screening alone to reduce alcohol consumption among high-risk adolescents presenting to Emergency Departments: three-arm pragmatic randomised trial

13:20 to 14:50

Networking zone 3 (N3)

Paolo Deluca

Oral presentation

3. Alcohol Assertive Outreach Treatment randomised controlled trial: a mixed methods economic evaluation

13:20 to 14:50

Networking zone 3 (N3)

Amy Wolstenholme

Discussion

Lessons for future clinical research trials and clinical practice

13:20 to 14:50

Networking zone 3 (N3)

Karl Mann

15:00

Keynote presentation

Early warnings and outbreaks: A sociological perspective

Richard Hartnoll – a seminal contributor to the development of the EMCDDA and drug epidemiology

15:00 to 15:30

Main stage

Paul Griffiths